MAIA Biotech Q2 net loss $4.5M; THIO-101 Phase 2 DCR 82%, 35 patients enrolled

MAIA Biotechnology, Inc.

2023-Q2 EPS reported -$0.72

Cash $9.1M at June 30, 2023; net loss $4.5M for Q2 2023 vs $3.3M loss in Q2 2022.
R&D expenses $2.6M, G&A $2.0M for the quarter.
THIO-101 Phase 2: 35 patients dosed as of July 2023; preliminary DCR 82% (9 of 11 patients) at first assessment.
First 2 patients alive without progression 10.2 and 8.5 months post-treatment, no additional therapy needed.
Filed second provisional patent for third telomere-targeting molecule MAIA-2021-029.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MAIA Biotechnology, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was approximately $4.5 million for the quarter ended June 30, 2023, as compared to net loss of approximately $3.

Period: the second quarter ended June 30, 2023
Net income: Net loss was approximately $4.5 million for the quarter ended June 30, 2023, as compared to net loss of approximately $3
Result: reported results

Exact text from the filing

MAIA Biotechnology, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended June 30, 2023

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

MAIA Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-205615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.